RAREFYING DISEASE OF THE SKELETON 



20- 



10- 



411 



UJ 



O 

 Q 



A Sr^^ I ST STUDY 

 A Sr^^ 2ND STUDY 

 o Ca"*^ 2ND STUDY 



J L. 



J L_^ L 



J I I L 



5 10 15 



DAYS POST INJECTION 



20 



Fig. 10. Chart showing urinai) excretion of Sv^'' and Ca^"^ in Case No. 8. 

 See Fig. 8. The total loss of Sr"*"' isotope during the first 3 days was only 23 

 per cent on polysaccharide therapy (first study), as compared with 37 per cent 

 on human growth hormone (second study). These results suggest more ac- 

 cretion of bone salts after treatment with polysaccharide, as compared with 

 osteoporotics treated with human growth hormone, or osteoporotics observed 

 without treatment of any kind. However, an enhanced resorption rate is tend- 

 ing to counteract the increased accretion, so the net effect over a period of 

 several weeks is small. 



nae and irregular staining of matrix of both haversian and interstitial 

 lamellae (Figs. 5B to 5G). After infusion of 3.0 gm of oxytetracy- 

 cline, onlv a rare osteon fluoresced, and the total uptake was only 

 1.0 y per gm of bone, or 84 per cent less than in nonosteoporotic 

 controls. The over-all impression gained from these observations was 

 that in Case No. 8 as much as 75 per cent of the bone in the tibia 

 was dead! 



